Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio and Remix Therapeutics Announce Merger Agreement
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference
Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio Announces 1-for-20 Reverse Stock Split
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Squarepoint Ops LLC Has $36,000 Stake in Passage Bio, Inc. (NASDAQ:PASG)
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Passage Bio assumed with an Outperform at Wedbush
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference
Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
All You Need to Know About Passage Bio (PASG) Rating Upgrade to Buy
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights